ストックスクリーナーアプリを入手
48.36
4.16%
-2.10
アフターアワーズ：
48.70
0.34
+0.70%
Exact Sciences Corp (EXAS) 最新ニュース
U.S. Biomarkers Market Projected to Surpass USD 106.03 Billion by 2034 | CAGR: 15.6% - industrytoday.co.uk
What analysts say about Exact Sciences Corporation stockExplosive wealth accumulation - PrintWeekIndia
What drives Exact Sciences Corporation stock priceBreakthrough investment results - PrintWeekIndia
How to Invest in Financial Technology Stocks Strategic Stock Investment PlanFree Trend-Following Techniques - jammulinksnews.com
Is Exact Sciences Corporation a good long term investmentAccelerated earnings growth - jammulinksnews.com
Top Stocks for Wealth Management AI Powered Stock Selection StrategyHigh-performance investment picks - jammulinksnews.com
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know - Yahoo Finance
Canaccord Genuity reiterates Buy rating on Exact Sciences stock ahead of study - Investing.com
Envestnet Asset Management Inc. Buys 13,004 Shares of Freshpet, Inc. (NASDAQ:FRPT) - Defense World
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet - Yahoo Finance
Exact Sciences to release Q2 2025 results on August 6 By Investing.com - Investing.com Canada
Exact Sciences to release Q2 2025 results on August 6 - Investing.com Australia
Press Release: Exact Sciences Schedules Second Quarter 2025 Earnings Call - 富途牛牛
Exact Sciences Schedules Second Quarter 2025 Earnings Call - The Globe and Mail
EXAS SEC FilingsExact Sciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Exact Sciences stock rises as Canaccord maintains Buy rating By Investing.com - Investing.com Canada
Exact’s Cancer-Screening Patent Invalidated in Geneoscopy Win - Bloomberg Law News
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences’ ’781 Patent - Business Wire
August 29th Options Now Available For EXACT Sciences Corp. (EXAS) - Nasdaq
Exact Sciences stock rises as Canaccord maintains Buy rating - Investing.com
Exact Sciences’ Oncodetect test receives Medicare coverage By Investing.com - Investing.com Nigeria
Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage - MarketScreener
Exact Sciences’ Oncodetect test receives Medicare coverage - Investing.com Australia
Exact Sciences announces Medicare coverage for Oncodetect(TM) molecular residual disease - MarketScreener
Exact Sciences gains Medicare coverage for colorectal cancer test - StreetInsider
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer - Business Wire
What Makes Exact Sciences (EXAS) a New Buy Stock - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance
Tom Still: Cancer tests continue to propel Exact Sciences - ehextra.com
Concerns Rise Over Exact Sciences Corp. (EXAS) Salesforce Reorganization Affecting Growth - Yahoo Finance
EXAS Shares Gain as Supreme Court Decision Clarifies Market Concerns | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Positive Impact from Supreme Court Decision | EXAS Stock News - GuruFocus
Gilead shares rise after US top court ruling on preventive coverage - Reuters
The 5 Most Interesting Analyst Questions From Exact Sciences’s Q1 Earnings Call - Yahoo Finance
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out - Benzinga
EXAS: Barclays Adjusts Price Target for Exact Sciences | EXAS Stock News - GuruFocus
QGEN vs. EXAS: Which Stock Is the Better Value Option? - Yahoo Finance
Barclays Adjusts Price Target for Exact Sciences (EXAS) in Q2 Ou - GuruFocus
Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap. - Yahoo Finance
Inside Wisconsin: Cancer tests continue to propel Exact Sciences, even in a skeptical age - hngnews.com
Exact Sciences in Madison unveils trio of cancer detection tests - The Cap Times
Tom Still: Cancer tests continue to propel Exact Sciences, even in time of research cuts - La Crosse Tribune
Insider Sell: Katherine Zanotti Sells Shares of Exact Sciences Corp (EXAS) - GuruFocus
Exact Sciences Shareholders Approve New Incentive Plan By Investing.com - Investing.com Canada
Exact Sciences Shareholders Approve New Incentive Plan - Investing.com
Exact Sciences Corp (EXAS) Shares Gap Down to $53.95 on Jun 12 - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Colorectal Cancer Screening Market Deep Research Report - openPR.com
Rhumbline Advisers Acquires 3,873 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Hologic Climbs 13% in a Month: How Should You Play the Stock? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Stock Position Increased by GAMMA Investing LLC - Defense World
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio? - Yahoo Finance
Global Colorectal Cancer Screening and Diagnostics Market to Reach $46.1 Billion by 2029 - The Malaysian Reserve
Corporate Wellness News from PRNEWSWIRE - Corporate Wellness Magazine
2.04%
1.25%
大文字化:
|
ボリューム (24 時間):